Compare FEED & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEED | GOVX |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.8M |
| IPO Year | 2014 | 1996 |
| Metric | FEED | GOVX |
|---|---|---|
| Price | $0.40 | $0.62 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 292.4K | ★ 356.2K |
| Earning Date | 04-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $318,000.00 | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $0.12 |
| 52 Week High | $6.09 | $4.40 |
| Indicator | FEED | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.